Clinical trial
Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)
NCT00247559 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00247559 |
|---|---|
| Title | Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet) |
| Official title | A Phase II, Multi-Centre, Randomised, Double-blind, Dose-Ranging Study Comparing the Efficacy and Safety of a Single Treatment With 15, 30 or 45 Units (Per Eye) of Dysport to Placebo in the Symptomatic Treatment of Lateral Canthal Lines (Crow's Feet) |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lateral Canthal Lines |
| Intervention type | Biological |
| Interventions | Botulinum toxin type A |
| Enrollment | 221 |
| Start date | May 1, 2004 |
| Primary completion | Apr 8, 2005 |
| Completion | Apr 8, 2005 |
| First posted | Nov 2, 2005 |
| Last update posted | Nov 22, 2019 |
| Countries | France, Germany, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: